Pregnancy Complications in Women with Polycystic Ovary Syndrome

ABSTRACT

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. There is an increasing body of evidence indicating that PCOS may have significant implications for pregnancy outcomes and long-term health of a woman and her offspring. Whether or not PCOS itself or the symptoms that coincide with PCOS, like obesity and fertility treatment, are responsible for these increased risks is a continuing matter of debate. Miscarriage rates among women with PCOS are believed to be increased compared with normal fertile women, although supporting evidence is limited. Pregnant women with PCOS experience a higher incidence of perinatal morbidity from gestational diabetes, pregnancy-induced hypertension, and preeclampsia. Their babies are at an increased risk of neonatal complications, such as preterm birth and admission at a neonatal intensive care unit. Pre-pregnancy, antenatal, and intrapartum care should be aimed at reducing these risks. The use of insulin sensitizing drugs to decrease hyperinsulinemic insulin resistance has been proposed during pregnancy to reduce the risk of developing preeclampsia or gestational diabetes. Although metformin appears to be safe, there are too few data from prospective, randomized controlled trials to support treatment during pregnancy.

Polycystic ovary syndrome - pregnancy complications - pregnancy outcome

REFERENCES

• 1 Franks S. Polycystic ovary syndrome.  N Engl J Med. 1995;  333 853-861
• 2 The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 41-47
• 3 Dunaif A. Insulin action in the polycystic ovary syndrome.  Endocrinol Metab Clin North Am. 1999;  28 341-359
• 4 Norman R J, Noakes M, Wu R, Davies M J, Moran L, Wang J X. Improving reproductive performance in overweight/obese women with effective weight management.  Hum Reprod Update. 2004;  10 267-280
• 5 Laven J S, Imani B, Eijkemans M J, Fauser B C. New approach to polycystic ovary syndrome and other forms of anovulatory infertility.  Obstet Gynecol Surv. 2002;  57 755-767
• 6 Wild R A. Long-term health consequences of PCOS.  Hum Reprod Update. 2002;  8 231-241
• 7 Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus.  Am J Med. 1995;  98 33S-39S
• 8 Haslam D W, James W P. Obesity.  Lancet. 2005;  366 1197-1209
• 9 Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.  Cochrane Database Syst Rev. 2000;  4 CD000410
• 10 Eijkemans M JC, Imani B, Mulders A GMG, Habbema J D, Fauser B CJM. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2).  Hum Reprod. 2003;  18 2357-2362
• 11 Ombelet W, Martens G, De Sutter P et al.. Perinatal outcome of 12 021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study.  Hum Reprod. 2006;  21 1025-1032
• 12 Fauser B C, Devroey P, Macklon N S. Multiple birth resulting from ovarian stimulation for subfertility treatment.  Lancet. 2005;  365 1807-1816
• 13 Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic?.  Clin Sci (Lond). 1999;  96 421-425
• 14 Sivan E, Boden G. Free fatty acids, insulin resistance, and pregnancy.  Curr Diab Rep. 2003;  3 319-322
• 15 Boomsma C M, Eijkemans M J, Hughes E G, Visser G H, Fauser B C, Macklon N S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.  Hum Reprod Update. 2006;  12 673-683
• 16 Diamant Y Z, Rimon E, Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease.  Eur J Obstet Gynecol Reprod Biol. 1982;  14 199-204
• 17 Levran D, Shoham Z, Habib D, Greenwald M, Nebel L, Mashiach S. Glucose tolerance in pregnant women following treatment for sterility.  Int J Fertil. 1990;  35 157-159
• 18 Wortsman J, de Angeles S, Futterweit W, Singh K B, Kaufmann R C. Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome.  J Reprod Med. 1991;  36 659-661
• 19 Cardenas M, Coulson C C, Legro R S. Infertile PCOS women do not have an increased risk for gestational diabetes or macrosomia [abstract]. American Society for Reproductive Medicine.  Scientific Oral and Poster Sessions Program Supplement. 1996;  85 1
• 20 Urman B, Sarac E, Dogan L, Gurgan T. Pregnancy in infertile PCOD patients. Complications and outcome.  J Reprod Med. 1997;  42 501-505
• 21 Fridstrom M, Nisell H, Sjoblom P, Hillensjo T. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia?.  Hypertens Pregnancy. 1999;  18 73-80
• 22 Radon P A, McMahon M J, Meyer W R. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome.  Obstet Gynecol. 1999;  94 194-197
• 23 Kashyap S, Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension.  J Reprod Med. 2000;  45 991-994
• 24 Vollenhoven B, Clark S, Kovacs G, Burger H, Healy D. Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins.  Aust N Z J Obstet Gynaecol. 2000;  40 54-58
• 25 Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome.  Hum Reprod. 2001;  16 226-229
• 26 Bjercke S, Dale P O, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome.  Gynecol Obstet Invest. 2002;  54 94-98
• 27 Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight.  Hum Reprod. 2003;  18 1438-1441
• 28 Turhan N O, Seckin N C, Aybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients.  Int J Gynaecol Obstet. 2003;  81 163-168
• 29 Weerakiet S, Srisombut C, Rojanasakul A, Panburana P, Thakkinstian A, Herabutya Y. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome.  Gynecol Endocrinol. 2004;  19 134-140
• 30 Sir-Petermann T, Hitchsfeld C, Maliqueo M et al.. Birth weight in offspring of mothers with polycystic ovarian syndrome.  Hum Reprod. 2005;  20 2122-2126
• 31 Jakubowicz D J, Iuorno M J, Jakubowicz S, Roberts K A, Nestler J E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 524-529
• 32 Gray R H, Wu L Y. Subfertility and risk of spontaneous abortion.  Am J Public Health. 2000;  90 1452-1454
• 33 Sagle M, Bishop K, Ridley N et al.. Recurrent early miscarriage and polycystic ovaries.  BMJ. 1988;  297 1027-1028
• 34 Homburg R. Pregnancy complications in PCOS.  Best Pract Res Clin Endocrinol Metab. 2006;  20 281-292
• 35 Dickey R P, Taylor S N, Curole D N, Rye P H, Pyrzak R. Incidence of spontaneous abortion in clomiphene pregnancies.  Hum Reprod. 1996;  11 2623-2628
• 36 Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles.  Clin Endocrinol (Oxf). 1990;  33 271-278
• 37 Creus M, Ordi J, Fabregues F et al.. The effect of different hormone therapies on integrin expression and pinopode formation in the human endometrium: a controlled study.  Hum Reprod. 2003;  18 683-693
• 38 Homburg R, Pap H, Brandes M, Huirne J, Hompes P, Lambalk C B. Endometrial biopsy during induction of ovulation with clomiphene citrate in polycystic ovary syndrome.  Gynecol Endocrinol. 2006;  22 506-510
• 39 Jain J K, Kuo J. Pregnancy outcomes with increased clomiphene citrate dose.  Gynecol Endocrinol. 2004;  19 141-145
• 40 Heijnen E M, Eijkemans M J, Hughes E G, Laven J S, Macklon N S, Fauser B C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.  Hum Reprod Update. 2006;  12 13-21
• 41 Homburg R, Armar N A, Eshel A, Adams J, Jacobs H S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.  BMJ. 1988;  297 1024-1026
• 42 Okon M A, Laird S M, Tuckerman E M, Li T C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.  Fertil Steril. 1998;  69 682-690
• 43 Tulppala M, Stenman U H, Cacciatore B, Ylikorkala O. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women.  Br J Obstet Gynaecol. 1993;  100 348-352
• 44 Tian L, Shen H, Lu Q, Norman R J, Wang J. Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment.  J Clin Endocrinol Metab. 2007;  92 1430-1433
• 45 Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage.  Lancet. 1990;  336 1141-1144
• 46 Mulders A G, Eijkemans M J, Imani B, Fauser B C. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility.  Reprod Biomed Online. 2003;  7 170-178
• 47 Wang J X, Davies M J, Norman R J. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment.  Hum Reprod. 2001;  16 2606-2609
• 48 Mulders A G, Laven J S, Eijkemans M J, Hughes E G, Fauser B C. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis.  Hum Reprod Update. 2003;  9 429-449
• 49 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-1174
• 50 Legro R S, Castracane V D, Kauffman R P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.  Obstet Gynecol Surv. 2004;  59 141-154
• 51 Metzger B E, Coustan D R. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee.  Diabetes Care. 1998;  21(Suppl 2) B161-B167
• 52 Hollander M H, Paarlberg K M, Huisjes A J. Gestational diabetes: a review of the current literature and guidelines.  Obstet Gynecol Surv. 2007;  62 125-136
• 53 Ornoy A. Growth and neurodevelopmental outcome of children born to mothers with pregestational and gestational diabetes.  Pediatr Endocrinol Rev. 2005;  3 104-113
• 54 Crowther C A, Hiller J E, Moss J R, McPhee A J, Jeffries W S, Robinson J S. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.  N Engl J Med. 2005;  352 2477-2486
• 55 Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus.  J Clin Endocrinol Metab. 1998;  83 1143-1150
• 56 Chu S Y, Callaghan W M, Kim S Y et al.. Maternal obesity and risk of gestational diabetes mellitus: a meta-analysis.  Diabetes Care. 2007;  30 2070-2076
• 57 National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy . Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.  Am J Obstet Gynecol. 2000;  183 S1-S22
• 58 Hu S, Leonard A, Seifalian A, Hardiman P. Vascular dysfunction during pregnancy in women with polycystic ovary syndrome.  Hum Reprod. 2007;  22 1532-1539
• 59 Wolf M, Sandler L, Munoz K, Hsu K, Ecker J L, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study.  J Clin Endocrinol Metab. 2002;  87 1563-1568
• 60 de Vries M J, Dekker G A, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study.  Eur J Obstet Gynecol Reprod Biol. 1998;  76 91-95
• 61 Cunningham F G, Leveno K J, Bloom S L, Hauth J C, Gilstrap L C, Wenstrom K D. Preterm birth. In: Seils A, Edmonson KG, Davis K Williams Obstetrics. 22nd ed. New York, NY; McGraw-Hill 2005: 855-880
• 62 Fauser B C, Devroey P, Macklon N S. Multiple birth resulting from ovarian stimulation for subfertility treatment.  Lancet. 2005;  365 1807-1816
• 63 Pederson J A. Hyperglycaemia-hyperinsulinism theory and birthweight. In: Yarauhar YW The Pregnant Diabetic and Her Neworn: Problems and Management. Baltimore, MD; Williams and Wilkins 1977: 211-220
• 64 Manikkam M, Crespi E J, Doop D D et al.. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep.  Endocrinology. 2004;  145 790-798
• 65 Barker D J. Maternal and fetal origins of coronary heart disease.  J R Coll Physicians Lond. 1994;  28 544-551
• 66 Sir-Petermann T, Maliqueo M, Angel B, Lara H E, Perez-Bravo F, Recabarren S E. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.  Hum Reprod. 2002;  17 2573-2579
• 67 Yu C K, Teoh T G, Robinson S. Obesity in pregnancy.  BJOG. 2006;  113 1117-1125
• 68 Checa M A, Requena A, Salvador C et al.. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome.  Hum Reprod Update. 2005;  11 375-390
• 69 Denno K M, Sadler T W. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis.  Teratology. 1994;  49 260-266
• 70 Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.  Fertil Steril. 2006;  86 658-663
• 71 Glueck C J, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy.  Hum Reprod. 2004;  19 1323-1330
• 72 Palomba S, Orio Jr F, Falbo A et al.. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 4068-4074
• 73 Moll E, Bossuyt P M, Korevaar J C, Lambalk C B, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.  BMJ. 2006;  332 1485
• 74 Salvesen K A, Vanky E, Carlsen S M. Metformin treatment in pregnant women with polycystic ovary syndrome-is reduced complication rate mediated by changes in the uteroplacental circulation?.  Ultrasound Obstet Gynecol. 2007;  29 433-437
• 75 Glueck C J, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome.  Diabet Med. 2004;  21 829-836
• 76 Vanky E, Salvesen K A, Heimstad R, Fougner K J, Romundstad P, Carlsen S M. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.  Hum Reprod. 2004;  19 1734-1740
• 77 Kovo M, Weissman A, Gur D, Levran D, Rotmensch S, Glezerman M. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy.  J Matern Fetal Neonatal Med. 2006;  19 415-419
• 78 Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial.  BMJ. 1996;  312 1508-1511
• 79 Homburg R, Levy T, Berkovitz D et al.. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.  Fertil Steril. 1993;  59 527-531
• 80 Hughes E, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome.  Cochrane Database Syst Rev. 2000;  2 CD000097
• 81 Homburg R. Pregnancy complications in PCOS.  Best Pract Res Clin Endocrinol Metab. 2006;  20 281-292
• 82 Al Ojaimi E H. Pregnancy outcomes after laparoscopic ovarian drilling in women with polycystic ovarian syndrome.  Saudi Med J. 2006;  27 519-525
• 83 Laven J S, Imani B, Eijkemans M J, Fauser B C. New approach to polycystic ovary syndrome and other forms of anovulatory infertility.  Obstet Gynecol Surv. 2002;  57 755-767
• 84 Venditti E M. Efficacy of lifestyle behavior change programs in diabetes.  Curr Diab Rep. 2007;  7 123-127
• 85 Knowler W C, Barrett-Connor E, Fowler S E et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 86 Norman R J, Noakes M, Wu R, Davies M J, Moran L, Wang J X. Improving reproductive performance in overweight/obese women with effective weight management.  Hum Reprod Update. 2004;  10 267-280
• 87 Kiddy D S, Hamilton-Fairley D, Bush A et al.. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 1992;  36 105-111
• 88 Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1995;  80 2586-2593
• 89 Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.  Hum Reprod. 1998;  13 1502-1505
• 90 Brankston G N, Mitchell B F, Ryan E A, Okun N B. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus.  Am J Obstet Gynecol. 2004;  190 188-193
• 91 Dempsey J C, Butler C L, Williams M A. No need for a pregnant pause: physical activity may reduce the occurrence of gestational diabetes mellitus and preeclampsia.  Exerc Sport Sci Rev. 2005;  33 141-149
• 92 Heijnen E M, Macklon N S, Fauser B C. What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment.  Hum Reprod. 2004;  19 1936-1938
• 93 Norman R J, Noakes M, Wu R, Davies M J, Moran L, Wang J X. Improving reproductive performance in overweight/obese women with effective weight management.  Hum Reprod Update. 2004;  10 267-280
• 94 Sattar N, Greer I A. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?.  BMJ. 2002;  325 157-160